High-resolution imaging to detect micrometer-scale cancer in pancreatic tissue

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial evaluates whether ultra-high resolution OCT can diagnose pancreatic cancer within resected specimens from patients with IPMN or pancreatic cancer. OCT images will be compared with standard histology to see how well OCT detects invasive cancer in the pancreatic duct. The imaging is performed on the surgical specimen and does not alter the tissue prior to pathology. Findings may guide future in vivo uses of OCT to identify early-stage pancreatic cancer during procedures. The study is conducted at Ohio State University Comprehensive Cancer Center and involves adults undergoing planned pancreatic resection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Immediate surgery cohort: Adult patients with pancreatic cancer or IPMN
* Immediate surgery cohort: Informed consent will be obtained
* Adult patients undergoing pancreatic resection for a presumed IPMN

Exclusion Criteria:

* Pregnant

Where it's running

• Ohio State University Comprehensive Cancer Center
  Columbus, Ohio, United States Recruiting

Study contacts

• Principal investigator: Mary Dillhoff, MD — Ohio State University Comprehensive Cancer Center
• Study coordinator: Ohio State University Comprehensive Cancer Center
• Email: OSUCCCClinicaltrials@osumc.edu
• Phone: 800-293-5066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Laryngopharyngeal injuries after breathing tube placement during general anesthesia

  This project sees how often and why people who had a breathing tube during general anesthesia developed hoarseness or other throat problems after non-ear–nose–throat surgery.

  Recruiting Zhejiang University · Hangzhou, Zhejiang and 1 other locations · NCT07359586

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Dual-target CAR-T therapy targeting mesothelin and CLDN18.2 for advanced pancreatic cancer

  This treatment will try sequential CAR‑T cell infusions that target mesothelin and CLDN18.2 in people with unresectable or metastatic pancreatic adenocarcinoma who have received prior systemic therapy.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066995

• Vanguard: a new blood test approach to screen for multiple cancers

  This study will test two different blood-based multi-cancer detection tests in adults 45–75 without cancer to see if they find cancers earlier than usual care.

  Recruiting at 46 sites National Cancer Institute (NCI) · Pleasanton, California and 45 other locations · NCT06995898

• Lanreotide versus placebo before surgery to prevent a pancreatic fistula

  This trial will see if giving lanreotide before a planned distal pancreatectomy lowers the risk of a pancreatic fistula in adults with pancreatic cancer or a suspicious pancreatic lesion.

  Recruiting at 18 sites Phase 3 SWOG Cancer Research Network · Birmingham, Alabama and 117 other locations · NCT06807437

• Testing XNW28012 in patients with advanced solid tumors who have not responded to standard treatments

  This study is testing a new treatment called XNW28012 in patients with advanced solid tumors who haven't had success with regular cancer therapies to see if it can help them.

  Recruiting at 24 sites Phase 1/2 Evopoint Biosciences Inc. · Hefei, Anhui and 23 other locations · NCT06799637

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.